Aura 2016 Supplementary data

Table S3.4e Key indicators for appropriateness of antimicrobial prescribing in hospitals, by jurisdiction, peer group, remoteness and funding type, combined national result, 2014

Number of hospitals	Number of prescriptions	Indication documented (%)	Surgical prophylaxis >24 hours (%)^a	Compliant with guidelines (%)	Noncompliant with guidelines (%)	Directed therapy (%)	Compliance with guidelines not available (%)	Not assessable for compliance with guidelines (%)	Appropriate (%)	Inappropriate (%)	Not assessable for appropriateness (%)
248	19 944	74.0	35.9	56.2	24.3	10.4	4.6	4.5	72.3	23.0	4.7

a Where surgical prophylaxis was selected as the indication (2785 prescriptions)

Note: No Tasmanian facilities participated in the National Antimicrobial Prescribing Survey in 2014.

Source: NAPS, 2014

Table S3.5 Appropriateness of antimicrobial prescribing in hospitals for the 20 most common indications, 2014

Rank of inappropriate prescribing	Rank of indication^a	Indication	Number of prescriptions	Appropriate (%)	Inappropriate (%)	Not assessable (%)
1	1	Surgical prophylaxis	2246	56.9	40.2	2.9
2	7	COPD: infective exacerbation	552	62.3	36.8	0.9
3	16	Cholecystitis	209	72.2	27.8	0.0
4	2	Community-acquired pneumonia	1936	73.9	25.0	1.1
5	4	Urinary tract infection	1156	73.1	25.0	1.9
6	5	Cellulitis/erysipelas	759	74.7	24.8	0.5
7	20	Appendicitis	159	76.7	22.6	0.6
8	9	Wound infection: surgical	369	74.5	21.4	4.1
9	10	Pneumonia: aspiration	362	77.1	21.3	1.7
10	8	Hospital-acquired pneumonia	401	77.8	21.2	1.0
11	17	Abscess	190	77.9	19.5	2.6
12	6	Sepsis: empiric therapy	563	80.8	17.1	2.1
13	15	Diverticulitis	219	85.8	14.2	0.0
14	14	Osteomyelitis	249	81.9	13.3	4.8
15	18	Sepsis: gram-negative bacteraemia	188	87.2	12.8	0.0
16	19	Diabetic infection (including foot)	169	88.2	11.2	0.6
17	12	Sepsis: gram-positive bacteraemia	261	89.7	10.0	0.4
18	13	Febrile neutropenia	258	92.6	6.6	0.8
19	3	Medical prophylaxis (bacterial, viral and fungal)	1320	89.9	6.4	3.6
20	11	Oral candidiasis	332	89.8	5.7	4.5

COPD = chronic obstructive pulmonary disease

a Rank in the 20 most common indications, where 1 is the most common indication

Source: NAPS, 2014